Dosing has begun in the second part of a Phase 1 clinical trial of GT-02287, an experimental oral therapy that Gain Therapeutics is developing as a treatment for Parkinson’s disease associated with mutations in the GBA1 gene. “Our Phase 1 clinical trial of GT-02287 remains on track…
Participating in high-intensity exercise can help protect the brain from progressive damage in Parkinson’s disease, a proof-of-concept imaging study suggests. “This is the first time imaging has been used to confirm that the biology of the brain in those suffering with Parkinson’s disease is changed by intense exercise,” Evan…
A doctoral student at Central Michigan University (CMU) is testing the efficacy of NewGait, a new device for mobility conditions — used here for people with Parkinson’s disease — that aims to help patients with gait issues to walk faster and better, according to a university press…
Zambon Biotech has entered into an exclusive deal with Amneal Pharmaceuticals for rights to seek approval and commercialize the oral treatment IPX203 for Parkinson’s disease in the European Union, U.K., and Switzerland. IPX203 is an experimental extended-release formulation of carbidopa and levodopa, designed to ease…
Visual and auditory cues delivered via an augmented reality (AR) headset were found to be feasible for adjusting gait among healthy young adults in a small recent study. Cues like the ones provided in the study have been proposed for improving gait in people with Parkinson’s disease, however, many…
Researchers at Iowa State University are exploring the benefits of music and dance, along with other activities, for people with Parkinson’s disease. Studies have shown that regular physical exercise can ease Parkinson’s motor symptoms, and that dancing may improve or slow the advancement of both motor and…
By mapping neurological circuits in the brain, an international team of researchers created a model of brain dysfunction that could help to better guide a surgical treatment for Parkinson’s disease and other brain disorders. Findings were published in Nature Nuroscience, in the study “Mapping dysfunctional circuits…
Patient enrollment has started in a Phase 1/2 clinical trial evaluating 18F-OP-801, Ashvattha Therapeutics’ investigational imaging agent to visualize brain inflammation in people with Parkinson’s disease and other neurodegenerative conditions, the company said in a press release. The ongoing trial (NCT05395624), which…
Targeting reactive astrocytes — star-shaped cells in the brain that play a supportive role for neurons but can promote brain inflammation when deregulated — could pave the way for novel therapies for neurodegenerative conditions like Parkinson’s disease, according to the findings of a new study. The study found that…
A potential anti-inflammatory therapy for Parkinson’s disease may be evaluated in clinical trials within the next year. The investigative treatment combines a low-dose formulation of interleukin-2 (IL-2) and granulocyte macrophage-colony stimulating factor (GM-CSF), two natural signaling molecules made in the body to help coordinate the activity of immune cells.
Get regular updates to your inbox.
